Ionis Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
Ionis Pharmaceuticals, Inc. (IONS) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $6.85 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2026-07-29
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $6.85M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $11.32M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $29.29M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $119.53M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2026-06-30 | $6.85M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $11.32M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $29.29M 10-K · filed 2026-02-26 |
| 2025-09-30 | $119.53M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $15.00M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $22.88M 10-Q · filed 2025-04-30 |
| 2024-12-31 | $52.02M 10-K · filed 2025-02-19 |
| 2024-09-30 | $110.56M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $331.61M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $201.07M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $331.85M 10-K · filed 2024-02-21 |
| 2023-09-30 | $470.21M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $400.43M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $486.92M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $499.38M 10-K · filed 2023-02-22 |
| 2022-09-30 | $266.57M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $76.95M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $36.30M 10-Q · filed 2022-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |